$1.2m cash, cash costs $1485 ($400 more than Dec Qtr). Assuming I am reading this right (?) it does not look like the turnaround that holders would have been praying for.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
AXN Rising demand, China's 'tech war' bans leaves this germanium explorer with significant investment potential
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025